Please login to the form below

Not currently logged in
Email:
Password:

felodipine

This page shows the latest felodipine news and features for those working in and with pharma, biotech and healthcare.

Recordati acquires AstraZeneca blood pressure brands

Recordati acquires AstraZeneca blood pressure brands

The agreement sees the Milan-based pharmaceutical group acquire rights to AZ’s Seloken ZOK (metoprolol succinate) and Logimax fixed dose combination (metoprolol succinate and felodipine) treatments in Europe.

Latest news

  • AZ adds gout drug Zurampic to asset sale AZ adds gout drug Zurampic to asset sale

    Last month, AZ sold European rights to its opioid-induced constipation treatment Moventig (naloxegol) to ProStrakan and transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur (isosorbide mononitrate) -

  • AZ offloads more products in slimming drive AZ offloads more products in slimming drive

    Meanwhile, earlier this week AZ also transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur (isosorbide mononitrate) - to China Medical System Holdings in a $500m deal.

  • Lifting the fog

    Oleptro (Angelini Labopharm). Major depressive disorder. US. Felodipine sustained-release. (Jiangbo Pharmaceuticals).

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2016 Deal Watch February 2016

    Being particularly active in out-licensing, AstraZeneca has granted a licence to China Medical System (CMS) in return for $310m to sell Plendil (felodipine), a calcium antagonist for hypertension in China. ... collaboration expanded. 500. AstraZeneca/

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics